A Study on the Efficacy and Safety of Intratonsillar Immunotherapy for Allergic Rhinitis
This is a prospective, open-label, positive parallel controlled, blinded endpoint clinical study designed to compare the safety and efficacy of Intratonsillar Immunotherapy of Standardized Dust Mite Allergen Extracts (Novo Helisen-Depot, Allergopharma, Merck, Germany) with Subcutaneous Immunotherapy in patients with Dust Mite Allergic Rhinitis. Participants will be evaluated for safety and efficacy throughout the entire three-year period.
• Voluntarily sign informed consent.
• Commitment to follow the research procedures and cooperate with the implementation of the entire research process.
• Diagnosis in accordance with ARIA guidelines, based on:
• ① Symptoms: Two or more symptoms such as paroxysmal sneezing, watery nose, nasal itching, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day. May be accompanied by eye symptoms such as tearing, eye itching, and eye redness.
• ② Signs: Common nasal mucosa pale, edema, nasal watery secretions.
⁃ Allergen test: Positive for skin prick test (SPT) and/or serum-specific IgE for at least one allergen, or positive for nasal provocation test.
• Have a history of allergic rhinitis caused by atopic allergens and one of the following:
• ① No significant relief after drug treatment.
• ② Do not want to continue taking medication for a long time.
• ③ Long-term drug treatment can produce adverse side effects.
⁃ Allergens cannot be effectively avoided in daily life.
• Women of childbearing age must ensure that they do not become pregnant during the treatment cycle.
• Must be between 5 and 65 years old.